Connect your AI

Myriad Genetics MYGN Common stock, par value (in dollars per share)

Common stock, par value (in dollars per share) at other companies

NeoGenomicsNEO

——

VeracyteVCYT

——

Guardant HealthGH

——

Natera, Inc.NTRA

——

GeneDx HoldingsWGS

——

Castle BiosciencesCSTL

——

Other financials

Income statement

Revenue$200.4M+2.3%

Gross profit$137.6M+2.5%

Operating income-$30.7M-5.9%

Net income-$34.1M-34,000%

EPS (diluted)-$0.36—

Balance sheet

Cash & equivalents$126.0M+24.8%

Total debt$211.5M+34.2%

Total equity$337.4M-52.1%

Total assets$673.7M-33.0%

Cash flow

Operating cash flow-$15.7M+3.7%

CapEx$18.8M+181%

Free cash flow-$19.7M+65.1%

Valuation

Market cap$512.85M+13.1%

Enterprise value$598.35M+17.3%

P/S0.6×+0.1×

Profitability

Gross margin70%0.0pp

Operating margin-46.9%-88.3pp

Net margin-48.2%-72.9pp

FCF margin-17%—

Returns & leverage

Return on equity-76.7%-98.4pp

Debt / equity0.6×+0.4×

Current ratio2.4×+0.5×

Where this comes from

Reported directly by Myriad Genetics in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The official record: Myriad Genetics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Myriad Genetics's common stock, par value (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Myriad Genetics's common stock, par value (in dollars per share)?: Myriad Genetics (MYGN) reported common stock, par value (in dollars per share) of $0.01 in Q1 2026.
How has Myriad Genetics's common stock, par value (in dollars per share) changed year-over-year?: Myriad Genetics's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0.01 to $0.01.